Vol - 25, Issue - 9
About the Journal
[This article belongs to Volume - 25, Issue - 9]
International Medical Journal
Journal ID : IMJ-26-08-2020-591
Total View : 493

Abstract : During the search for treatments for COVID-19, clinical trials for testing hydroxychloroquine were interrupted by the WHO already on May 25, 2020 after publication of a paper in the magazine The Lancet [2] that stated that patients who had received hydroxychloroquine presented mortality rates of 35% due to severe cardiac arrhythmias. This paper was withdrawn thirteen days after its publication because it was questioned by 120 scientists of various nationalities [3], both as regards the data collected and as regards the method, and on June 2, 2020 also eighty Italian medical doctors sent a letter to The Lancet and to the WHO in which they criticized the scientific contents of the paper. [4] Then, on June 3, 2020, Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, allowed restart of recruitment of patients in tests regarding hydroxychloroquine in the Solidarity trial. [5] The Recovery trial then became the principal study on which the WHO based its final decision to confirm for all drug agencies suspension of use of hydroxychloroquine for the treatment of COVID-19

Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates